Most Read Articles
Elvira Manzano, 24 Jun 2015
Adding sitagliptin, a dipeptidyl peptidase 4 inhibitor (DPP-4), to usual care in patients with glycaemic equipoise does not increase the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), according to the TECOS* study.
Christina Lau, 15 Jun 2016
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant reductions in major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular (CV) risk in the LEADER (Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcomes Results) trial.
Elvira Manzano, 21 Nov 2016
Newer metabolic agents, including trimetazidine, represent ancillary forms of prophylactic antianginal therapy and may be useful in patients with stable coronary artery disease (SCAD) who are unsuitable for percutaneous or surgical revascularization, says a leading cardiologist at the recent AFCC 2016.
Pearl Toh, 14 Jun 2016
Cardiovascular magnetic resonance (CMR) is a stronger predictor of major adverse cardiovascular events (MACE) compared with single-photon emission computed tomography (SPECT), according to the CE-MARC* study.

An Optimized Strategy to Address Residual Cardiovascular (CV) Risk and Diabetic Retinopathy (DR)

24 Oct 2016
At the 7th Annual Congress of the Malaysian Endocrine & Metabolic Society (MAC7), Professor Dr Chan Siew Pheng and Dr Gavin Tan spoke on the recent evidence to improve residual CV risk and DR respectively, in type 2 diabetes mellitus (T2DM). Highlights of their presentations are summarized below.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 24 Jun 2015
Adding sitagliptin, a dipeptidyl peptidase 4 inhibitor (DPP-4), to usual care in patients with glycaemic equipoise does not increase the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), according to the TECOS* study.
Christina Lau, 15 Jun 2016
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant reductions in major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular (CV) risk in the LEADER (Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcomes Results) trial.
Elvira Manzano, 21 Nov 2016
Newer metabolic agents, including trimetazidine, represent ancillary forms of prophylactic antianginal therapy and may be useful in patients with stable coronary artery disease (SCAD) who are unsuitable for percutaneous or surgical revascularization, says a leading cardiologist at the recent AFCC 2016.
Pearl Toh, 14 Jun 2016
Cardiovascular magnetic resonance (CMR) is a stronger predictor of major adverse cardiovascular events (MACE) compared with single-photon emission computed tomography (SPECT), according to the CE-MARC* study.